Palonosetron Plus 1-Day Dexamethasone for the Prevention of Nausea and Vomiting Due to Moderately Emetogenic Chemotherapy: Effect of Established Risk Factors on Treatment Outcome in a Phase III Trial

Journal of Supportive Oncology

Volumn 10, Issue 2, 2012, Pages 65-71

  Celio, Luigi ^a   Denaro, Angela ^a,b   Agustoni, Francesco ^a   Bajetta, Emilio ^a,c  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Centro Sociale Oncologico   (Italy)

^c Istituto di Oncologia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; IRINOTECAN; METOCLOPRAMIDE; OXALIPLATIN; PALONOSETRON;

ADULT; AGE DISTRIBUTION; ALCOHOL CONSUMPTION; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; COLORECTAL CANCER; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA AND VOMITING; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SINGLE DRUG DOSE; TREATMENT OUTCOME;

AGE FACTORS; ANTIEMETICS; ANTINEOPLASTIC AGENTS; DEXAMETHASONE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; ISOQUINOLINES; MALE; MIDDLE AGED; NAUSEA; QUINUCLIDINES; RISK FACTORS; SEROTONIN RECEPTOR AGONISTS; VOMITING;

EID: 84857659084     PISSN: 15446794     EISSN: 1879596X     Source Type: Journal    
DOI: 10.1016/j.suponc.2011.06.007     Document Type: Article

References (15)

1. Sharma R., Tobin P., Clarke S.J. Management of chemotherapy-induced nausea, vomiting, oral mucositis, diarrhoea. Lancet Oncol 2005, 6:93-102.
2. Hesketh P.J. Chemotherapy-induced nausea and vomiting. N Engl J Med 2008, 358:2482-2494.
3. NCCN Guidelines, version 1.2011. Antiemesis Accessed December 20, 2010. http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf.
4. Roila F., Herrstedt J., Aapro M., et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 2010, 21(suppl 5):v232-v243.
5. Vardy J., Chiew K.S., Galica J., et al. Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer 2006, 94:1011-1015.
6. Celio L., Denaro A., Canova S., et al. Clinical update on palonosetron in the management of chemotherapy-induced nausea and vomiting. Tumori 2008, 94:447-452.
7. Celio L., Frustaci S., Denaro A., et al. Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial. Support Care Cancer 2011, 19(8):1217-1225.
8. Schwartzberg L.S. Chemotherapy-induced nausea and vomiting: clinician and patient perspectives. J Support Oncol 2007, 5(suppl 1):5-12.
9. Roila F., Hesketh P.J., Herrstedt J. Antiemetic Subcommitte of the Multinational Association of Supportive Care in Cancer. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 2006, 17:20-28.
10. Warr D.G., Hesketh P.J., Gralla R.J., et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005, 23:2822-2830.
11. Feyer P., Jordan K. Updated and new trends in antiemetic therapy: the continuing need for novel therapies. Ann Oncol 2011, 22:30-38.
12. Nevidjon B., Chaudhary R. Controlling emesis: evolving challenges, novel strategies. J Support Oncol 2010, 8(suppl 2):1-10.
13. Olver I., Molassiotis A., Aapro M., et al. Antiemetic research: future directions. Support Care Cancer 2011, 19(suppl 1):S49-S55.
14. Aapro M., Fabi A., Nolè F., et al. Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol 2010, 21:1083-1088.
15. Grunberg S.M., Dugan M., Muss H., et al. Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy. Support Care Cancer 2009, 17:589-594.